<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ami_virus_1\PMC7100368\results\search\tropicalVirus\results.xml">
  <result pre="Media S.A. pmcid: 7100368 doi: 10.3389/fmicb.2020.00362 : Microbiology: Review Defeat" exact="Dengue" post="and Zika Viruses With a One-Two Punch of Vaccine"/>
  <result pre="pmcid: 7100368 doi: 10.3389/fmicb.2020.00362 : Microbiology: Review Defeat Dengue and" exact="Zika" post="Viruses With a One-Two Punch of Vaccine and Vector"/>
  <result pre="is permitted which does not comply with these terms. Abstract" exact="Dengue" post="virus (DENV) and Zika virus (ZIKV) are two mosquito-borne"/>
  <result pre="not comply with these terms. Abstract Dengue virus (DENV) and" exact="Zika" post="virus (ZIKV) are two mosquito-borne flaviviruses afflicting nearly half"/>
  <result pre="be manifested as hemorrhagic fever and hemorrhagic shock syndrome, and" exact="ZIKV" post="infection has been linked to increased incidence of peripheral"/>
  <result pre="these infectious diseases are either non-satisfactory or entirely lacking. Because" exact="DENV" post="and ZIKV have much similarities in genomic and structural"/>
  <result pre="diseases are either non-satisfactory or entirely lacking. Because DENV and" exact="ZIKV" post="have much similarities in genomic and structural features, almost"/>
  <result pre="countermeasures against both. Here, we review the existing knowledge on" exact="DENV" post="and ZIKV regarding epidemiology, molecular virology, protective immunity and"/>
  <result pre="both. Here, we review the existing knowledge on DENV and" exact="ZIKV" post="regarding epidemiology, molecular virology, protective immunity and vaccine development,"/>
  <result pre="vaccine and vector blockade to overcome antibody-dependent enhancement and defeat" exact="Dengue" post="and Zika viruses. dengue virus Zika virus epidemiology virology"/>
  <result pre="vector blockade to overcome antibody-dependent enhancement and defeat Dengue and" exact="Zika" post="viruses. dengue virus Zika virus epidemiology virology protective immunity"/>
  <result pre="antibody-dependent enhancement and defeat Dengue and Zika viruses. dengue virus" exact="Zika" post="virus epidemiology virology protective immunity vaccine mosquitoes Funding National"/>
  <result pre="Shanghai Municipality10.13039/501100003399 fig-count: table-count: equation-count: ref-count: page-count: word-count: Epidemiology of" exact="Dengue" post="Virus and Zika Virus Dengue virus (DENV) is the"/>
  <result pre="table-count: equation-count: ref-count: page-count: word-count: Epidemiology of Dengue Virus and" exact="Zika" post="Virus Dengue virus (DENV) is the most prevalent mosquito-borne"/>
  <result pre="ref-count: page-count: word-count: Epidemiology of Dengue Virus and Zika Virus" exact="Dengue" post="virus (DENV) is the most prevalent mosquito-borne flavivirus that"/>
  <result pre="population in 128 countries and regions (Brady et al., 2012)." exact="Zika" post="virus (ZIKV) is another virus that has caught public"/>
  <result pre="during 2014â€&quot;2016 (Baud et al., 2017). The transmitting vectors of" exact="DENV" post="and ZIKV are Aedes mosquitoes, mainly A. aegypti and"/>
  <result pre="(Baud et al., 2017). The transmitting vectors of DENV and" exact="ZIKV" post="are Aedes mosquitoes, mainly A. aegypti and A. albopictus"/>
  <result pre="but also have features that are distinct from each other." exact="Dengue" post="viruses are antigenically classified into four serotypes that originate"/>
  <result pre="(mostly children) progress to more severe forms of dengue disease," exact="Dengue" post="Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS), in"/>
  <result pre="severe forms of dengue disease, Dengue Hemorrhagic Fever (DHF) and" exact="Dengue" post="Shock Syndrome (DSS), in which plasma leakage and hemorrhagic"/>
  <result pre="al., 1984; Guzman et al., 2013; Katzelnick et al., 2017)." exact="Dengue" post="like disease has been a public health problem for"/>
  <result pre="the only licensed vaccine is far from satisfactory. In comparison," exact="Zika" post="virus emerged more recently as a public health concern."/>
  <result pre="recently as a public health concern. The historical documents of" exact="Zika" post="virus started as its first isolation from a monkey"/>
  <result pre="virus started as its first isolation from a monkey in" exact="Zika" post="forest of Uganda in 1947 (Dick et al., 1952)."/>
  <result pre="(Duffy et al., 2009; Grard et al., 2014). Symptoms of" exact="ZIKV" post="infection including fever, arthralgia, rash and conjunctivitis were presented"/>
  <result pre="was observed for the first time to be associated with" exact="Zika" post="virus infection, implicating the neurotropic feature of Zika virus"/>
  <result pre="associated with Zika virus infection, implicating the neurotropic feature of" exact="Zika" post="virus (Musso et al., 2018); additionally, detection of viral"/>
  <result pre="were also documented during this outbreak. Nevertheless, the threat of" exact="Zika" post="virus was not recognized until 2015â€&quot;2016 when it caused"/>
  <result pre="from northeast region of Brazil (Faria et al., 2017), where" exact="Zika" post="virus infected 63% peoples in Salvador. The virus spread"/>
  <result pre="and pacific islands (Baud et al., 2017). In Europe, travel-associated" exact="ZIKV" post="cases were reported in most EU (European Union) countries"/>
  <result pre="the Caribbean (Spiteri et al., 2017). During the Brazil outbreak," exact="ZIKV" post="has been suspected to persistently replicate in multiple organs"/>
  <result pre="babies (Weaver et al., 2016). Soon after, the association between" exact="Zika" post="virus infection and microcephaly was confirmed by extensive studies"/>
  <result pre="2017; Szaba et al., 2018). Furthermore, in vivo replication of" exact="ZIKV" post="in neuron, placenta and fetus was also verified by"/>
  <result pre="Mlakar et al., 2016). Since early 2016, WHO has declared" exact="Zika" post="virus disease as a public health emergency of global"/>
  <result pre="health emergency of global concern. It should be noted that" exact="ZIKV" post="and DENV spread through the same Aedes mosquito vectors"/>
  <result pre="of global concern. It should be noted that ZIKV and" exact="DENV" post="spread through the same Aedes mosquito vectors in overlapping"/>
  <result pre="and genomic structures should be of value. Virological Features of" exact="Dengue" post="Virus and Zika Virus Both Dengue virus and Zika"/>
  <result pre="should be of value. Virological Features of Dengue Virus and" exact="Zika" post="Virus Both Dengue virus and Zika virus belong to"/>
  <result pre="value. Virological Features of Dengue Virus and Zika Virus Both" exact="Dengue" post="virus and Zika virus belong to the genus of"/>
  <result pre="of Dengue Virus and Zika Virus Both Dengue virus and" exact="Zika" post="virus belong to the genus of flavivirus in the"/>
  <result pre="NS2A, NS2B, NS3, NS4A, NS5). Generally, the sequence homology between" exact="DENV" post="and ZIKV polyprotein is 55â€&quot;56%, whereas the homology among"/>
  <result pre="NS3, NS4A, NS5). Generally, the sequence homology between DENV and" exact="ZIKV" post="polyprotein is 55â€&quot;56%, whereas the homology among four serotype"/>
  <result pre="infected cells form the major architecture of viral particles of" exact="ZIKV" post="and DENV, whereas the non-structural proteins (except for NS1)"/>
  <result pre="recent study at 9 Ã… resolution showed structure of immature" exact="Zika" post="virus and demonstrated that there was a regular but"/>
  <result pre="capsid inside the membrane, implying a dynamical morphological alteration during" exact="Zika" post="virus maturation (Prasad et al., 2017). Despite minor differences,"/>
  <result pre="(Prasad et al., 2017). Despite minor differences, the structures of" exact="DENV" post="and ZIKV are generally similar. A noted difference exists"/>
  <result pre="al., 2017). Despite minor differences, the structures of DENV and" exact="ZIKV" post="are generally similar. A noted difference exists in a"/>
  <result pre="exists in a region surrounding glycosylation site at Asn154 of" exact="ZIKV" post="envelope protein and Asn153 of DENV envelope protein, these"/>
  <result pre="site at Asn154 of ZIKV envelope protein and Asn153 of" exact="DENV" post="envelope protein, these sites may influence virus transmission and"/>
  <result pre="surface. Functionally, in contrast to the mature virus, the immature" exact="DENV" post="and ZIKV are non-infectious, however, such immature virus particle"/>
  <result pre="in contrast to the mature virus, the immature DENV and" exact="ZIKV" post="are non-infectious, however, such immature virus particle can also"/>
  <result pre="et al., 2017; Bailey et al., 2018). Cell Tropism of" exact="Dengue" post="Virus and Zika Virus Transmission of DENV and ZIKV"/>
  <result pre="Bailey et al., 2018). Cell Tropism of Dengue Virus and" exact="Zika" post="Virus Transmission of DENV and ZIKV are mainly mediated"/>
  <result pre="Cell Tropism of Dengue Virus and Zika Virus Transmission of" exact="DENV" post="and ZIKV are mainly mediated by Aedes mosquitoes. When"/>
  <result pre="of Dengue Virus and Zika Virus Transmission of DENV and" exact="ZIKV" post="are mainly mediated by Aedes mosquitoes. When human is"/>
  <result pre="monocyte was the principle target cell among PBMCs for both" exact="DENV" post="and ZIKV infection, as well as the main mediators"/>
  <result pre="the principle target cell among PBMCs for both DENV and" exact="ZIKV" post="infection, as well as the main mediators for ADE"/>
  <result pre="circulating CD14 + monocytes were the primary cellular targets of" exact="ZIKV" post="infection in PBMCs (Foo et al., 2017; Michlmayr et"/>
  <result pre="disseminate through the circulatory and lymphatic system, dengue virus and" exact="Zika" post="virus spread to different tissues and organs. Dengue virus"/>
  <result pre="virus and Zika virus spread to different tissues and organs." exact="Dengue" post="virus infects primary vascular endothelial cells, splenic macrophage and"/>
  <result pre="2007; Dalrymple and Mackow, 2012). In contrast, besides these tissues," exact="Zika" post="virus also replicates in uterus and many immune privileged"/>
  <result pre="neuropathology, congenital disorders, and damages to reproductive organs. So far," exact="Zika" post="virus has been found to infect a wide range"/>
  <result pre="and Diamond, 2017; Qian et al., 2017). Several investigations indicated" exact="Zika" post="virus infects endothelial cells, the key component of blood"/>
  <result pre="tissue barriers, a fact that may help to explain how" exact="Zika" post="virus crosses blood brain barrier and placental barrier (Liu"/>
  <result pre="al., 2017). However, it is still controversial as to whether" exact="Zika" post="virus infection alters endothelial barrier integrity. A recent study"/>
  <result pre="infection alters endothelial barrier integrity. A recent study showed that" exact="ZIKV" post="infection of human umbilical vein endothelial cells (HUVECs) increased"/>
  <result pre="et al., 2019), whereas some other studies have demonstrated that" exact="Zika" post="virus directionally infected polarized epithelial cells from apical side"/>
  <result pre="of cell monolayer integrity (Tamhankar and Patterson, 2019). Understanding of" exact="ZIKV" post="cell tropism and dissemination across blood tissue barriers will"/>
  <result pre="dissemination across blood tissue barriers will help to better elucidate" exact="Zika" post="pathology, and provide opportunity for the development of efficient"/>
  <result pre="tissue tropism should also been considered during development of prophylactic" exact="ZIKV" post="vaccine. Its criteria for protective efficacies need to include"/>
  <result pre="Shan et al., 2017; Zou et al., 2018). Different from" exact="DENV" post="vaccine candidates, ZIKV vaccine might have to elicit higher"/>
  <result pre="2017; Zou et al., 2018). Different from DENV vaccine candidates," exact="ZIKV" post="vaccine might have to elicit higher level of immune"/>
  <result pre="studies of the incidence of fetal microcephaly in women received" exact="ZIKV" post="vaccine are also necessary in clinical trials. The Benefits"/>
  <result pre="clinical trials. The Benefits and Limitations of the Only Licensed" exact="Dengue" post="Vaccine With effort that lasted two decades, the first"/>
  <result pre="itself. Last but not the least, whether the emergence of" exact="Zika" post="virus in DENV endemic regions and prior ZIKV immunity"/>
  <result pre="not the least, whether the emergence of Zika virus in" exact="DENV" post="endemic regions and prior ZIKV immunity in vaccine recipients"/>
  <result pre="emergence of Zika virus in DENV endemic regions and prior" exact="ZIKV" post="immunity in vaccine recipients will affect the efficacy of"/>
  <result pre="unknown, and whether vaccination by Dengvaxia will enhance or prevent" exact="Zika" post="virus infection is also uncertain. As co-circulation of two"/>
  <result pre="uncertain. As co-circulation of two viruses and complicated interference between" exact="Dengue" post="and Zika virus-specific immunity have already been observed (Bardina"/>
  <result pre="co-circulation of two viruses and complicated interference between Dengue and" exact="Zika" post="virus-specific immunity have already been observed (Bardina et al.,"/>
  <result pre="al., 2019), it is worthwhile taking the probable influence of" exact="ZIKV" post="into consideration during dengue vaccine development. Therefore, either the"/>
  <result pre="new vaccines must be applied judiciously in epidemic regions. Other" exact="Dengue" post="and Zika Vaccines Currently in Clinical Trials Other Dengue"/>
  <result pre="must be applied judiciously in epidemic regions. Other Dengue and" exact="Zika" post="Vaccines Currently in Clinical Trials Other Dengue Vaccines in"/>
  <result pre="Other Dengue and Zika Vaccines Currently in Clinical Trials Other" exact="Dengue" post="Vaccines in Clinical Trials Besides the approved dengue vaccine"/>
  <result pre="protein vaccine, and one DNA vaccine (Table 1). TABLE 1" exact="Dengue" post="vaccines in clinical trials. Name Vaccine type Immunogen Developer"/>
  <result pre="on the backbone of attenuated DENV-4 NIAID/Butantan Institute Phase III" exact="DENV" post="subunit V180 Subunit protein Ectodomain (N-terminal 80%) of envelope"/>
  <result pre="antibody and provide protection against challenge with multiple serotypes of" exact="DENV" post="in murine and non-human primate models (Clements et al.,"/>
  <result pre="al., 2012), much of its results have not been published." exact="Zika" post="Vaccines in Clinical Trials In contrast to Dengue vaccines,"/>
  <result pre="been published. Zika Vaccines in Clinical Trials In contrast to" exact="Dengue" post="vaccines, Zika vaccines have only been developed recently since"/>
  <result pre="Zika Vaccines in Clinical Trials In contrast to Dengue vaccines," exact="Zika" post="vaccines have only been developed recently since the large"/>
  <result pre="Zika vaccines have only been developed recently since the large" exact="ZIKV" post="outbreaks in 2015â€&quot;2016. Multiple candidates are under development simultaneously,"/>
  <result pre="II clinical trials will be discussed (Table 2). TABLE 2" exact="Zika" post="vaccines in clinical trials. Name Vaccine type Immunogen Developers"/>
  <result pre="injection &amp;amp; electroporation GeneOne life science Inc./Inovio Pharmaceuticals Phase I" exact="ZIKV" post="purified inactivated vaccine (ZPIV) Inactivated vaccine Formalin-inactivated whole virus"/>
  <result pre="Valneva Australia GmbH Phase I rZIKV/D4delta30 Chimeric live attenuated vaccine" exact="ZIKV" post="prM and E genes inserted to DEN4delta30 NIAID Phase"/>
  <result pre="genes inserted to DEN4delta30 NIAID Phase I MV-ZIKA Viral vector" exact="ZIKV" post="prM and E genges inserted to measles virus vector"/>
  <result pre="prM and E ModernaTX, Inc. Phase I The most advanced" exact="Zika" post="vaccine candidates is a DNA vaccine containing Zika virus"/>
  <result pre="most advanced Zika vaccine candidates is a DNA vaccine containing" exact="Zika" post="virus prM and E genes (VRC5283) that is being"/>
  <result pre="DNA vaccine GLS-5700 (developed by GeneOne/Inovio) containing consensus sequences of" exact="ZIKV" post="prM and E genes, delivered via intradermal injection followed"/>
  <result pre="from vaccine recipients protected 92% immune deficient mice from lethal" exact="ZIKV" post="challenge (Tebas et al., 2017). The development of inactivated"/>
  <result pre="ZIKV challenge (Tebas et al., 2017). The development of inactivated" exact="Zika" post="vaccine was started soon after the ZIKV outbreaks. There"/>
  <result pre="development of inactivated Zika vaccine was started soon after the" exact="ZIKV" post="outbreaks. There are currently two purified inactivated Zika vaccine"/>
  <result pre="after the ZIKV outbreaks. There are currently two purified inactivated" exact="Zika" post="vaccine candidates in Phase I clinical trials, they were"/>
  <result pre="IgG from vaccine recipients to mice prior to challenge with" exact="ZIKV" post="led to reduced viremia in mice, indicating its potential"/>
  <result pre="a similar strategy for DENV-2 vaccine TV003/TV005, recombinant live attenuated" exact="Zika" post="vaccine has been constructed with the backbone of attenuated"/>
  <result pre="I clinical trial, and might be tested in combination with" exact="DENV" post="vaccine TV005 in the future (ID: NCT03611946) (Durbin and"/>
  <result pre="Measles vaccine virus has also been adapted to construct chimeric" exact="ZIKV" post="vaccine. One of such vaccine, MV-ZIKA, has been developed"/>
  <result pre="lipid nanoparticle-encapsulated modified mRNA has also been used to develop" exact="Zika" post="vaccine. An mRNA that contains prM-E genes of ZIKV"/>
  <result pre="develop Zika vaccine. An mRNA that contains prM-E genes of" exact="ZIKV" post="and optimized 5â€² and 3â€² untranslated sequences with type-1"/>
  <result pre="high titers (âˆ¼1/100,000) of neutralizing antibodies, and conferred protection against" exact="ZIKV" post="challenge in mice (Richner et al., 2017a). An mRNA-based"/>
  <result pre="Phase I clinical trial (ID: NCT03014089). Besides, other forms of" exact="ZIKV" post="vaccine, such as protein based subunit vaccine (Medina et"/>
  <result pre="et al., 2019; Slon-Campos et al., 2019) and live attenuated" exact="Zika" post="vaccines (Richner et al., 2017b; Xie et al., 2018;"/>
  <result pre="at the pre-clinical stage. Considering the cross-reactivity and ADE between" exact="ZIKV" post="and DENV, newly developed ZIKV vaccine should also be"/>
  <result pre="the cross-reactivity and ADE between ZIKV and DENV, newly developed" exact="ZIKV" post="vaccine should also be tested for DENV enhancement activity."/>
  <result pre="DENV, newly developed ZIKV vaccine should also be tested for" exact="DENV" post="enhancement activity. This additional requirement will likely to be"/>
  <result pre="requirement will likely to be a huge obstacle for both" exact="ZIKV" post="and DENV vaccines. Protective Immunity Against Dengue and Zika"/>
  <result pre="likely to be a huge obstacle for both ZIKV and" exact="DENV" post="vaccines. Protective Immunity Against Dengue and Zika Viruses Protective"/>
  <result pre="obstacle for both ZIKV and DENV vaccines. Protective Immunity Against" exact="Dengue" post="and Zika Viruses Protective Antibody Response Although various antibodies"/>
  <result pre="both ZIKV and DENV vaccines. Protective Immunity Against Dengue and" exact="Zika" post="Viruses Protective Antibody Response Although various antibodies targeting different"/>
  <result pre="indicated that E domain III was the predominant targets for" exact="DENV" post="neutralizing antibodies, and antibodies to this region are mainly"/>
  <result pre="III specific neutralizing antibodies only constitute a small proportion of" exact="DENV" post="antibody repertoire. Mapping antibody epitope using recombinant envelope proteins,"/>
  <result pre="Rouvinski et al., 2015). On the contrary, the importance of" exact="ZIKV" post="EDIII specific antibodies has been shown directly in some"/>
  <result pre="neutralization (Stettler et al., 2016). Additionally, using two cohorts of" exact="ZIKV" post="infected individuals from Mexico and Brazil, it was revealed"/>
  <result pre="the levels of antibodies specific for the lateral ridge of" exact="ZIKV" post="E domain III were positively correlated with sera neutralization"/>
  <result pre="quaternary epitopes formed between E domains II and III of" exact="Zika" post="virus were demonstrated to be both protective and therapeutic"/>
  <result pre="al., 2016; Hasan et al., 2017; Collins et al., 2019)." exact="DENV" post="and ZIKV show high level of structure homology between"/>
  <result pre="Hasan et al., 2017; Collins et al., 2019). DENV and" exact="ZIKV" post="show high level of structure homology between their envelope"/>
  <result pre="EDE1 antibodies, one subset of EDE antibodies originally isolated from" exact="DENV" post="patients, has been shown to potently neutralize Zika virus"/>
  <result pre="isolated from DENV patients, has been shown to potently neutralize" exact="Zika" post="virus in vitro and provides protection against lethal challenge"/>
  <result pre="virus in vitro and provides protection against lethal challenge of" exact="Zika" post="virus in mice. These antibodies recognize a conserved conformational"/>
  <result pre="antibodies that have broader footprints covering N153 glycosylation site of" exact="DENV" post="E proteins, these antibodies can also cross-neutralize ZIKV at"/>
  <result pre="site of DENV E proteins, these antibodies can also cross-neutralize" exact="ZIKV" post="at high concentrations (Fernandez et al., 2017; Abbink et"/>
  <result pre="al., 2017; Abbink et al., 2018; Figure 1A). In contrast," exact="ZIKV" post="neutralization antibodies targeting quaternary epitopes identified so far, such"/>
  <result pre="and EDE2 were isolated mainly from patients of acute secondary" exact="DENV" post="infection, whereas A9E and G9E were isolated from DENV"/>
  <result pre="secondary DENV infection, whereas A9E and G9E were isolated from" exact="DENV" post="naÃ¯ve ZIKV patients at 6 months after the onset"/>
  <result pre="infection, whereas A9E and G9E were isolated from DENV naÃ¯ve" exact="ZIKV" post="patients at 6 months after the onset of illness."/>
  <result pre="Rouvinski et al. (2017). Collectively, neutralization antibodies to dengue or" exact="Zika" post="viruses are mainly constituted of type specific EDIII antibodies,"/>
  <result pre="in vitro studies have already demonstrated that most antibodies to" exact="DENV" post="or ZIKV prM and E proteins have the potential"/>
  <result pre="studies have already demonstrated that most antibodies to DENV or" exact="ZIKV" post="prM and E proteins have the potential to enhance"/>
  <result pre="al., 2010; de Alwis et al., 2014). Further investigation on" exact="Zika" post="and dengue monoclonal antibodies indicates that antibody concentrations that"/>
  <result pre="to in vitro studies using human samples, ADE of heterotypic" exact="DENV" post="infection has been more stringently demonstrated in mouse models."/>
  <result pre="has been more stringently demonstrated in mouse models. Administering heterotypic" exact="DENV" post="immune sera or viral-specific monoclonal antibodies to AG129 immune"/>
  <result pre="(Zellweger et al., 2010). Consistently, clinical evidence of ADE in" exact="DENV" post="infection has been reported previously. Infants born to dengue"/>
  <result pre="6â€&quot;9 months of age, due to the decay of maternal-derived" exact="DENV" post="antibodies (Halstead, 2003). Further, the increased risk of hospitalization"/>
  <result pre="(Katzelnick et al., 2017). More significantly, a cross-serocomplex ADE between" exact="ZIKV" post="and DENV has also been reproduced in mouse model."/>
  <result pre="al., 2017). More significantly, a cross-serocomplex ADE between ZIKV and" exact="DENV" post="has also been reproduced in mouse model. DENV and"/>
  <result pre="ZIKV and DENV has also been reproduced in mouse model." exact="DENV" post="and WNV immune sera were both found to enhance"/>
  <result pre="DENV has also been reproduced in mouse model. DENV and" exact="WNV" post="immune sera were both found to enhance Zika virus"/>
  <result pre="DENV and WNV immune sera were both found to enhance" exact="Zika" post="virus infection in mice (Bardina et al., 2017). Also,"/>
  <result pre="accelerated fetal resorption (Leborgne et al., 2019). Reciprocally, maternally acquired" exact="Zika" post="virus antibodies also enhanced dengue disease severity in mice"/>
  <result pre="are not as clear. Two studies did not show enhanced" exact="Zika" post="virus infection in macaques that were infected by DENV"/>
  <result pre="enhanced Zika virus infection in macaques that were infected by" exact="DENV" post="either 420 days or 2.8 years before experiments (McCracken"/>
  <result pre="should be noted that the interval between primary and secondary" exact="DENV" post="infections is critical for disease severity, and DENV ADE"/>
  <result pre="and secondary DENV infections is critical for disease severity, and" exact="DENV" post="ADE in human has only occurred within a relatively"/>
  <result pre="has only occurred within a relatively narrow range of pre-existing" exact="DENV" post="antibody concentration (Katzelnick et al., 2017). In dengue infected"/>
  <result pre="usually 12 months or longer, but unknown for enhancement of" exact="Zika" post="virus infection. Limited data from a long-term cohort study"/>
  <result pre="long-term cohort study in Brazil before and after the 2015" exact="ZIKV" post="outbreak have found that the pre-existing DENV NS1 specific"/>
  <result pre="after the 2015 ZIKV outbreak have found that the pre-existing" exact="DENV" post="NS1 specific IgG3 antibody within 4â€&quot;6 months of infection"/>
  <result pre="of infection was positively associated with the risk of subsequent" exact="ZIKV" post="infection, but high titer of total IgG to DENV"/>
  <result pre="subsequent ZIKV infection, but high titer of total IgG to" exact="DENV" post="was associated with protection against the acquisition of ZIKV"/>
  <result pre="to DENV was associated with protection against the acquisition of" exact="ZIKV" post="infection (Rodriguez-Barraquer et al., 2019). Our previous study using"/>
  <result pre="convalescent dengue patients also revealed that stronger cross-serocomplex ADE of" exact="ZIKV" post="infection in PBMC appeared more often in sera obtained"/>
  <result pre="appeared more often in sera obtained within 3 months of" exact="DENV" post="infection (Li et al., 2018). These results are supportive"/>
  <result pre="two infections are important factors for determining cross-serocomplex enhancement between" exact="ZIKV" post="and DENV. Collectively, ADE is now considered to be"/>
  <result pre="development. Despite the impact of prior cross-serocomplex immunity for subsequent" exact="ZIKV" post="or DENV infections are clinically unknown, candidate vaccines that"/>
  <result pre="the impact of prior cross-serocomplex immunity for subsequent ZIKV or" exact="DENV" post="infections are clinically unknown, candidate vaccines that provide protection"/>
  <result pre="development. T Cell Responses Aside from the double-edged antibody responses," exact="DENV" post="and ZIKV infections also elicit strong T cell responses"/>
  <result pre="Cell Responses Aside from the double-edged antibody responses, DENV and" exact="ZIKV" post="infections also elicit strong T cell responses of dubious"/>
  <result pre="al., 2010). A subsequent human cohort study further illustrated that" exact="DENV" post="specific CD8 + T cell responses played protective roles"/>
  <result pre="specific CD8 + T cell responses played protective roles against" exact="DENV" post="infection in an HLA-linked manner (Weiskopf et al., 2013)."/>
  <result pre="full scope of T cell responses toward conserved epitopes. Similarly," exact="ZIKV" post="specific CD8 + T cells were also first showed"/>
  <result pre="Ngono et al., 2017; Huang et al., 2017), and human" exact="ZIKV" post="CD8 + T cells were revealed to have cytotoxic"/>
  <result pre="its antiviral cytotoxicity might be associated with neurological pathology in" exact="ZIKV" post="infection, the pre-existence of specific CD8 + T cells"/>
  <result pre="disease (Huang et al., 2017; Jurado et al., 2018). Whether" exact="ZIKV" post="CD4 + T cell responses are necessary for virus"/>
  <result pre="peptide immunization have been demonstrated to protect host from subsequent" exact="ZIKV" post="infection (Hassert et al., 2018; Elong Ngono et al.,"/>
  <result pre="2019). In one cohort study conducted in dengue endemic countries," exact="ZIKV" post="specific CD8 + T cell epitopes were found to"/>
  <result pre="al., 2017b). Cross-reactive T cell responses were often observed between" exact="DENV" post="and ZIKV, because of their homology at amino acid"/>
  <result pre="and ZIKV, because of their homology at amino acid level." exact="DENV" post="specific memory CD8 + T cells could cross-react with"/>
  <result pre="DENV specific memory CD8 + T cells could cross-react with" exact="Zika" post="virus and protected mice from subsequent lethal ZIKV challenge"/>
  <result pre="cross-react with Zika virus and protected mice from subsequent lethal" exact="ZIKV" post="challenge (Wen et al., 2017a). Adoptive transfer of DENV"/>
  <result pre="lethal ZIKV challenge (Wen et al., 2017a). Adoptive transfer of" exact="DENV" post="CD8 + T cells to pregnant mice inhibited Zika"/>
  <result pre="of DENV CD8 + T cells to pregnant mice inhibited" exact="Zika" post="virus replication in placenta and increased the survival of"/>
  <result pre="increased the survival of fetus (Regla-Nava et al., 2018). In" exact="DENV" post="convalescent patients, memory CD4 + and CD8 + T"/>
  <result pre="+ T cells could be activated by peptides derived from" exact="ZIKV" post="capsid and NS3 proteins, and the activated CD8 +"/>
  <result pre="proteins, and the activated CD8 + T cells could kill" exact="ZIKV" post="infected cells in vitro (Lim et al., 2018). Nevertheless,"/>
  <result pre="the cross-reactive CD4 + T cells are few, evidence for" exact="ZIKV" post="specific memory T cells cross-react with DENV antigens is"/>
  <result pre="few, evidence for ZIKV specific memory T cells cross-react with" exact="DENV" post="antigens is still lacking. All above demonstrate that T"/>
  <result pre="is an important element of adaptive immunity toward dengue and" exact="Zika" post="virus, and T cell component should be considered in"/>
  <result pre="the existing knowledge of vaccine immunology and protective immunity to" exact="DENV" post="and ZIKV, it is predicted that an ideal dengue"/>
  <result pre="and ZIKV, it is predicted that an ideal dengue or" exact="Zika" post="vaccine should induce both humoral and cellular immune response"/>
  <result pre="response to ensure full protection. Universal B Cell Vaccines for" exact="DENV" post="and ZIKV Previous investigation on dengue and Zika vaccine"/>
  <result pre="ensure full protection. Universal B Cell Vaccines for DENV and" exact="ZIKV" post="Previous investigation on dengue and Zika vaccine mainly focused"/>
  <result pre="Vaccines for DENV and ZIKV Previous investigation on dengue and" exact="Zika" post="vaccine mainly focused on the B cell immunity, aiming"/>
  <result pre="Because of the complex interaction among antibody responses to four" exact="DENV" post="serotypes and ZIKV, an ideal dengue vaccine should elicit"/>
  <result pre="broadly neutralizing antibodies that cross-react with all serotypes of viruses." exact="Zika" post="vaccines developed independently need to be able to trigger"/>
  <result pre="the antibody responses elicited by intact or recombinant dengue or" exact="Zika" post="viruses still maintain the dual functions of neutralization and"/>
  <result pre="strains. Epitopes on â€œprâ€� peptides are probably exposed on immature" exact="ZIKV" post="virus surface and elicit abundant ADE inducing antibodies, similar"/>
  <result pre="elicit abundant ADE inducing antibodies, similar to what happened in" exact="DENV" post="infected patients. The same issue must be dealt with"/>
  <result pre="selection and quality control. In most subunit candidate vaccines of" exact="DENV" post="and ZIKV, soluble EDIII or E80 as antigens were"/>
  <result pre="Figure 1B). Consistently, in a recent study, the covalently stabilized" exact="ZIKV" post="E dimer has successfully elicited protective antibody responses against"/>
  <result pre="ZIKV E dimer has successfully elicited protective antibody responses against" exact="ZIKV" post="infection in mice, without causing cross-reactivity to dengue viruses"/>
  <result pre="mice, without causing cross-reactivity to dengue viruses or ADE of" exact="DENV" post="(Slon-Campos et al., 2019). Currently, both Zika EDIII and"/>
  <result pre="or ADE of DENV (Slon-Campos et al., 2019). Currently, both" exact="Zika" post="EDIII and Dengue tetravalent EDIII vaccines are under development."/>
  <result pre="DENV (Slon-Campos et al., 2019). Currently, both Zika EDIII and" exact="Dengue" post="tetravalent EDIII vaccines are under development. The EDIII component"/>
  <result pre="vivo protection varies among four serotypes of dengue viruses or" exact="Zika" post="virus, to adjust the balance among immune responses in"/>
  <result pre="E80, further incorporation of consensus E80 monomers derived from both" exact="DENV" post="and ZIKV to a stabilized dimer might help to"/>
  <result pre="incorporation of consensus E80 monomers derived from both DENV and" exact="ZIKV" post="to a stabilized dimer might help to present most"/>
  <result pre="cell memory response is another essential aim for dengue or" exact="Zika" post="vaccine. In clinical trial of CYD-TDV, GMT of antibody"/>
  <result pre="we should be able to construct a universal dengue and" exact="Zika" post="B cell vaccine. Furthermore, with suitable heterologous vaccines in"/>
  <result pre="responses that have limited ADE effect. T Cell Vaccines for" exact="DENV" post="and ZIKV In contrast to the extensive attention on"/>
  <result pre="have limited ADE effect. T Cell Vaccines for DENV and" exact="ZIKV" post="In contrast to the extensive attention on B cell"/>
  <result pre="experienced than dengue naÃ¯ve vaccine recipients. As a chimera of" exact="Dengue" post="virus and YF-17D vaccine, CYD-TDV mainly elicited YFV specific"/>
  <result pre="chimera of Dengue virus and YF-17D vaccine, CYD-TDV mainly elicited" exact="YFV" post="specific T cell responses through YFV non-structural proteins, of"/>
  <result pre="vaccine, CYD-TDV mainly elicited YFV specific T cell responses through" exact="YFV" post="non-structural proteins, of which reactivity to dengue virus was"/>
  <result pre="infection, dengue specific memory T cell responses were boosted by" exact="YFV" post="cross-reactive epitopes in seropositive recipients and contributed to protection."/>
  <result pre="is complementary to traditional B cell vaccines for defense against" exact="DENV" post="and ZIKV. Distinct from B cell epitopes, T cell"/>
  <result pre="restricted. Some HLA-linked protective epitopes have already been identified for" exact="DENV" post="and ZIKV, it is worthwhile to study epitope distribution"/>
  <result pre="in a study of immunogenicity and protection efficacy of multiepitope" exact="DENV" post="NS3 DNA vaccine in Balb/c mice, and it demonstrated"/>
  <result pre="T cell responses. TAK-003 and TV003 containing non-structural proteins of" exact="DENV" post="have been shown to elicit both antibody responses and"/>
  <result pre="to induce protective T cell immunity toward four serotypes of" exact="DENV" post="and ZIKV simultaneously, and whether cross-reactive T cell responses"/>
  <result pre="protective T cell immunity toward four serotypes of DENV and" exact="ZIKV" post="simultaneously, and whether cross-reactive T cell responses could be"/>
  <result pre="we propose an improvement of the strategy for dengue and" exact="Zika" post="virus vaccine development by inclusion of T cell epitopes"/>
  <result pre="effect in vivo. Vector Blockade Through NS1 Antibodies As both" exact="DENV" post="and ZIKV are transmitted through Aedes mosquitoes, countermeasures that"/>
  <result pre="vivo. Vector Blockade Through NS1 Antibodies As both DENV and" exact="ZIKV" post="are transmitted through Aedes mosquitoes, countermeasures that block the"/>
  <result pre="blood meal. Furthermore, we demonstrated that NS1 antigenemia also determined" exact="ZIKV" post="infectivity in mosquitoes. Specifically, comparing with ZIKV Asian strains"/>
  <result pre="antigenemia also determined ZIKV infectivity in mosquitoes. Specifically, comparing with" exact="ZIKV" post="Asian strains that were isolated before recent outbreaks, contemporary"/>
  <result pre="enhanced infectivity in mosquitoes. This mechanism helps to explain how" exact="ZIKV" post="of Asian lineage acquired the ability to rapidly spread"/>
  <result pre="host pathology, some of which are completely opposite. Previously, soluble" exact="DENV" post="NS1 was found to contribute directly to vascular leakage"/>
  <result pre="al., 2017). Further study on DENV, WNV, YFV, JEV, and" exact="ZIKV" post="revealed that the effect of NS1 on cell permeability"/>
  <result pre="patterns for different viruses (Puerta-Guardo et al., 2019). In addition," exact="DENV" post="NS1 also facilitates viral immune evasion through inhibiting complement"/>
  <result pre="initiate complement dependent cytotoxicity (CDC). Recent investigations show that transferring" exact="ZIKV" post="NS1 antibodies from human or vaccinated mice to IFN"/>
  <result pre="apoptosis of endothelial cells, and thus leading to pathology in" exact="DENV" post="infections (Falconar, 1997; Lin et al., 2005; Cheng et"/>
  <result pre="in human vaccine might offer a better chance for defeating" exact="DENV" post="and ZIKV epidemics. Special Concerns in the Development of"/>
  <result pre="vaccine might offer a better chance for defeating DENV and" exact="ZIKV" post="epidemics. Special Concerns in the Development of ZIKV and"/>
  <result pre="DENV and ZIKV epidemics. Special Concerns in the Development of" exact="ZIKV" post="and DENV Vaccines Because ZIKV and DENV have different"/>
  <result pre="ZIKV epidemics. Special Concerns in the Development of ZIKV and" exact="DENV" post="Vaccines Because ZIKV and DENV have different pathogenic characteristics"/>
  <result pre="Concerns in the Development of ZIKV and DENV Vaccines Because" exact="ZIKV" post="and DENV have different pathogenic characteristics and tropism, special"/>
  <result pre="the Development of ZIKV and DENV Vaccines Because ZIKV and" exact="DENV" post="have different pathogenic characteristics and tropism, special issues should"/>
  <result pre="the development of vaccines to these viruses, especially for prophylactic" exact="ZIKV" post="vaccines which are currently under development by several research"/>
  <result pre="and to reduce mortality in lethal infection murine models. However," exact="ZIKV" post="has the ability to infect and replicate in reproductive"/>
  <result pre="Prisant et al., 2016; Miner and Diamond, 2017). Therefore, during" exact="ZIKV" post="vaccine development, specified criteria for protective efficacies should include"/>
  <result pre="and decreased damages to reproductive systems. In contrast, evaluation of" exact="DENV" post="vaccine in disease models mainly includes blockage of vascular"/>
  <result pre="dengue, and hospitalization were the three major parameters to evaluate" exact="DENV" post="vaccine candidates (Hadinegoro et al., 2015; Biswal et al.,"/>
  <result pre="In addition to these three parameters, for the evaluation of" exact="ZIKV" post="vaccine, other parameters might have to be included, such"/>
  <result pre="syndrome, fetal brain development abnormality). To fulfill the criteria above," exact="ZIKV" post="vaccine strategy should also be modified, since the characteristics"/>
  <result pre="weaker T cell responses were elicited by a live attenuated" exact="ZIKV" post="vaccine during pregnancy, comparing to that in non-pregnant mice."/>
  <result pre="required to protect pregnant mice and block vertical transmission of" exact="ZIKV" post="(Shan et al., 2019). Such evidence warrants a vaccine"/>
  <result pre="better approaches to defeat dengue viruses. The sudden outbreaks of" exact="Zika" post="virus has brought additional difficulties to solve the dengue"/>
  <result pre="additional difficulties to solve the dengue problem, because the pre-existing" exact="ZIKV" post="antibodies have the potential to enhance DENV infection, and"/>
  <result pre="because the pre-existing ZIKV antibodies have the potential to enhance" exact="DENV" post="infection, and antibodies elicited by dengue vaccines also have"/>
  <result pre="elicited by dengue vaccines also have the potential to augment" exact="ZIKV" post="infection. However, as for any other scientific challenges before,"/>
  <result pre="any other scientific challenges before, the large global outbreak of" exact="ZIKV" post="has brought in extensive investigations on flavivirus virology, immunology,"/>
  <result pre="approaches are necessary. FIGURE 3 Urban cycle of dengue and" exact="Zika" post="virus transmission can be blocked at multiple steps by"/>
  <result pre="multiple steps by vaccine elicited immune responses. Both dengue and" exact="Zika" post="viruses are transmitted between human through mosquitoes in urban"/>
  <result pre="T cells can be activated by infected cells that present" exact="DENV" post="or ZIKV peptides in the context of MHC-I molecules,"/>
  <result pre="can be activated by infected cells that present DENV or" exact="ZIKV" post="peptides in the context of MHC-I molecules, and activated"/>
  <result pre="existing knowledge on epidemiology, molecular virology, and vaccine development of" exact="DENV" post="and ZIKV; and updated our understanding on protective immunity"/>
  <result pre="and ZIKV; and updated our understanding on protective immunity against" exact="DENV" post="and ZIKV. We have also discussed recent discoveries on"/>
  <result pre="a potential one-two punch strategy that overcomes ADE and defeats" exact="Dengue" post="and Zika viruses through a combination of vaccines and"/>
  <result pre="one-two punch strategy that overcomes ADE and defeats Dengue and" exact="Zika" post="viruses through a combination of vaccines and vector blockade."/>
  <result pre="(2018). Therapeutic and protective efficacy of a dengue antibody against" exact="Zika" post="infection in rhesus monkeys.Nat. Med.24721â€&quot;723. 10.1038/s41591-018-0056-029867228 AvirutnanP.FuchsA.HauhartR. E.SomnukeP.YounS.DiamondM. S.et"/>
  <result pre="(2019). Antibodies elicited by an ns1-based vaccine protect mice against" exact="Zika" post="Virus.MBio10e2861â€&quot;e2818. 10.1128/mBio.02861-1830940710 BaileyM. J.DuehrJ.DulinH.BroeckerF.BrownJ. A.ArumemiF. O.et al. (2018). Human"/>
  <result pre="10.1128/mBio.02861-1830940710 BaileyM. J.DuehrJ.DulinH.BroeckerF.BrownJ. A.ArumemiF. O.et al. (2018). Human antibodies targeting" exact="Zika" post="virus NS1 provide protection against disease in a mouse"/>
  <result pre="Commun.9:4560. 10.1038/s41467-018-07008-030385750 BardinaS. V.BunducP.TripathiS.DuehrJ.FrereJ. J.BrownJ. A.et al. (2017). Enhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunity.Science356175â€&quot;180. 10.1126/science.aal436528360135 BarnettR. (2017)."/>
  <result pre="(2016). Infection dynamics in a traveller with persistent shedding of" exact="Zika" post="virus RNA in semen for six months after returning"/>
  <result pre="2016.Euro Surveill21:30316. 10.2807/1560-7917.ES.2016.21.32.3031627542178 BaudD.GublerD. J.SchaubB.LanteriM. C.MussoD. (2017). An update on" exact="Zika" post="virus infection.Lancet3902099â€&quot;2109. 10.1016/S0140-6736(17)31450-228647173 BeattyP. R.Puerta-GuardoH.KillingbeckS. S.GlasnerD. R.HopkinsK.HarrisE. (2015). Dengue"/>
  <result pre="on Zika virus infection.Lancet3902099â€&quot;2109. 10.1016/S0140-6736(17)31450-228647173 BeattyP. R.Puerta-GuardoH.KillingbeckS. S.GlasnerD. R.HopkinsK.HarrisE. (2015)." exact="Dengue" post="virus NS1 triggers endothelial permeability and vascular leak that"/>
  <result pre="L.SimmonsC. P.MacagnoA.SimonelliL.QuyenN. T.et al. (2010). The human immune response to" exact="Dengue" post="virus is dominated by highly cross-reactive antibodies endowed with"/>
  <result pre="mice.J. Virol.759731â€&quot;9740. 10.1128/JVI.75.20.9731-9740.200111559806 BlaneyJEJr.SatheN. S.GoddardL.HansonC. T.RomeroT. A.HanleyK. A.et al. (2008)." exact="Dengue" post="virus type 3 vaccine candidates generated by introduction of"/>
  <result pre="J. Trop. Med. Hyg.7274â€&quot;81. 10.4269/ajtmh.2005.72.7415728870 CamposG. S.BandeiraA. C.SardiS. I. (2015)." exact="Zika" post="virus outbreak. Bahia, Brazil.Emerg. Infect. Dis.211885â€&quot;1886. 10.3201/eid2110.15084726401719 CapedingM. R.TranN."/>
  <result pre="phase 3, randomised, observer-masked, placebo-controlled trial.Lancet3841358â€&quot;1365. 10.1016/S0140-6736(14)61060-625018116 CareyD. E. (1971)." exact="Chikungunya" post="and dengue: a case of mistaken identity?J. Hist. Med."/>
  <result pre="on platelets and inhibit platelet aggregation.Mol. Immunol.47398â€&quot;406. 10.1016/j.molimm.2009.08.03319822367 ClarkeT. (2002)." exact="Dengue" post="virus: break-bone fever.Nature416672â€&quot;674. 10.1038/416672a11961522 ClementsD. E.CollerB. A.LiebermanM. M.OgataS.WangG.HaradaK. E.et"/>
  <result pre="A.Gimblet-OchiengC.LiouG. A.JadiR. S.MetzS. W.et al. (2019). Human antibody response to" exact="Zika" post="targets type-specific quaternary structure epitopes.JCI Insight4:e123588. 10.1172/jci.insight.12458830996133 CostaS. M.YorioA."/>
  <result pre="USA.Vaccine315047â€&quot;5054. 10.1016/j.vaccine.2013.08.08824021313 de AlwisR.WilliamsK. L.SchmidM. A.LaiC. Y.PatelB.SmithS. A.et al. (2014)." exact="Dengue" post="viruses are enhanced by distinct populations of serotype cross-reactive"/>
  <result pre="enhance dengue virus infection in humans.Science328745â€&quot;748. 10.1126/science.118518120448183 DejnirattisaiW.SupasaP.WongwiwatW.RouvinskiA.Barba-SpaethG.DuangchindaT.et al. (2016)." exact="Dengue" post="virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika"/>
  <result pre="with dengue virus.Nat. Immunol.16170â€&quot;177. 10.1038/ni.305825501631 DickG. W.KitchenS. F.HaddowA. J. (1952)." exact="Zika" post="virus. I. Isolations and serological specificity.Trans. R Soc. Trop."/>
  <result pre="10.1073/pnas.101086710720837518 DuffyM. R.ChenT. H.HancockW. T.PowersA. M.KoolJ. L.LanciottiR. S.et al. (2009)." exact="Zika" post="virus outbreak on Yap Island. Federated States of Micronesia.N."/>
  <result pre="children with dengue.J. Immunol.1847281â€&quot;7287. 10.4049/jimmunol.090326220483770 DurbinA.Wilder-SmithA. (2017). An update on" exact="Zika" post="vaccine developments.Expert Rev. Vaccines16781â€&quot;787. 10.1080/14760584.2017.134530928633549 DurbinA. P.KirkpatrickB. D.PierceK. K.ElwoodD.LarssonC."/>
  <result pre="and role of the CD8(+) T cell response during primary" exact="Zika" post="Virus Infection in Mice.Cell Host Microbe2135â€&quot;46. 10.1016/j.chom.2016.12.01028081442 Elong NgonoA.YoungM."/>
  <result pre="CD4+ T cells promote humoral immunity and viral control during" exact="Zika" post="virus infection.PLoS Pathog.15:e1007474. 10.1371/journal.ppat.100747430677097 FalconarA. K. (1997). The dengue"/>
  <result pre="M.ThezeJ.de JesusJ. G.GiovanettiM.et al. (2017). Establishment and cryptic transmission of" exact="Zika" post="virus in Brazil and the Americas.Nature546406â€&quot;410. 10.1038/nature2240128538727 FatimaK.SyedN. I."/>
  <result pre="to the dengue virus E-dimer epitope have therapeutic activity against" exact="Zika" post="virus infection.Nat. Immunol.181261â€&quot;1269. 10.1038/ni.384928945244 FooS. S.ChenW.ChanY.BowmanJ. W.ChangL. C.ChoiY.et al."/>
  <result pre="infection.Nat. Immunol.181261â€&quot;1269. 10.1038/ni.384928945244 FooS. S.ChenW.ChanY.BowmanJ. W.ChangL. C.ChoiY.et al. (2017). Asian" exact="Zika" post="virus strains target CD14(+) blood monocytes and induce M2-skewed"/>
  <result pre="in mice.Cell Host Microbe24, 743.E5â€&quot;750.e5. 10.1016/j.chom.2018.09.01530439343 GaucherD.TherrienR.KettafN.AngermannB. R.BoucherG.Filali-MouhimA.et al. (2008)." exact="Yellow fever" post="vaccine induces integrated multilineage and polyfunctional immune responses.J. Exp."/>
  <result pre="M.HuZ.YamshchikovG.RothwellR. S.et al. (2018). Safety, tolerability, and immunogenicity of two" exact="Zika" post="virus DNA vaccine candidates in healthy adults: randomised, open-label,"/>
  <result pre="Clinical Trial.J. Infect. Dis.2121032â€&quot;1041. 10.1093/infdis/jiv17925791116 GlasnerD. R.RatnasiriK.Puerta-GuardoH.EspinosaD. A.BeattyP. R.HarrisE. (2017)." exact="Dengue" post="virus NS1 cytokine-independent vascular leak is dependent on endothelial"/>
  <result pre="endothelial glycocalyx components.PLoS Pathog.13:e1006673. 10.1371/journal.ppat.100667329121099 GoveroJ.EsakkyP.ScheafferS. M.FernandezE.DruryA.PlattD. J.et al. (2016)." exact="Zika" post="virus infection damages the testes in mice.Nature540438â€&quot;442. 10.1038/nature2055627798603 GovindarajanD.MeschinoS.GuanL.ClementsD."/>
  <result pre="efficacy in nonhuman primates.Vaccine334105â€&quot;4116. 10.1016/j.vaccine.2015.06.06726144900 GrardG.CaronM.MomboI. M.NkogheD.Mboui OndoS.JiolleD.et al. (2014)." exact="Zika" post="virus in Gabon (Central Africa)â€&quot;2007: a new threat from"/>
  <result pre="GriffinB. D.MuthumaniK.WarnerB. M.MajerA.HaganM.AudetJ.et al. (2017). DNA vaccination protects mice against" exact="Zika" post="virus-induced damage to the testes.Nat. Commun.8:15743. 10.1038/ncomms1574328589934 GrifoniA.AngeloM. A.LopezB.Oâ€™RourkeP."/>
  <result pre="(2017b). Prior dengue virus exposure shapes T Cell Immunity to" exact="Zika" post="Virus in Humans.J. Virol.91:e01469-17. 10.1128/JVI.01469-1728978707 GrifoniA.Costa-RamosP.PhamJ.TianY.RosalesS. L.SeumoisG.et al. (2018)."/>
  <result pre="edge: transcriptional profiling reveals multifunctional and cytotoxic antiviral responses of" exact="Zika" post="Virus-Specific CD8(+) T Cells.J. Immunol.2013487â€&quot;3491. 10.4049/jimmunol.180109030413672 GublerD. J. (1987)."/>
  <result pre="Zika Virus-Specific CD8(+) T Cells.J. Immunol.2013487â€&quot;3491. 10.4049/jimmunol.180109030413672 GublerD. J. (1987)." exact="Dengue" post="and dengue hemorrhagic fever in the Americas.P R Health"/>
  <result pre="of dengue viruses.Adv. Virus Res.60421â€&quot;467. 10.1016/s0065-3527(03)60011-414689700 HalsteadS. B.DansL. F. (2019)." exact="Dengue" post="infection and advances in dengue vaccines for children.Lancet Child"/>
  <result pre="Hyg.32154â€&quot;156. 10.4269/ajtmh.1983.32.1546824120 HasanS. S.MillerA.SapparapuG.FernandezE.KloseT.LongF.et al. (2017). A human antibody against" exact="Zika" post="virus crosslinks the E protein to prevent infection.Nat. Commun.8:14722."/>
  <result pre="E.DiPaoloR. J.BrienJ. D.PintoA. K. (2018). CD4+T cells mediate protection against" exact="Zika" post="associated severe disease in a mouse model of infection.PLoS"/>
  <result pre="(2017). CD8(+) T Cell Immune Response in Immunocompetent Mice during" exact="Zika" post="Virus Infection.J. Virol.91e900â€&quot;e917. 10.1128/JVI.00900-1728835502 JessieK.FongM. Y.DeviS.LamS. K.WongK. T. (2004)."/>
  <result pre="Transcriptome profiling reveals Pro-Inflammatory cytokines and matrix metalloproteinase activation in" exact="Zika" post="Virus infected human umbilical vein endothelial cells.Front. Pharmacol.10:642. 10.3389/fphar.2019.0064231249527"/>
  <result pre="cells.Front. Pharmacol.10:642. 10.3389/fphar.2019.0064231249527 KhaiboullinaS. F.RibeiroF. M.UppalT.MartynovaE. V.RizvanovA. A.VermaS. C. (2019)." exact="Zika" post="virus transmission through blood tissue barriers.Front. Microbiol.10:1465. 10.3389/fmicb.2019.0146531333605 KirkpatrickB."/>
  <result pre="in duchenne muscular dystrophy patients.Cell Immunol.342:103780. 10.1016/j.cellimm.2018.03.00429571923 LiC.XuD.YeQ.HongS.JiangY.LiuX.et al. (2016)." exact="Zika" post="virus disrupts neural progenitor development and leads to microcephaly"/>
  <result pre="and function of human monoclonal antibodies contribute to enhancement of" exact="Zika" post="virus infectivity in vitro.Sci. China Life Sci.601396â€&quot;1398. 10.1007/s11427-017-9192-029134418 LiM.ZhaoL.ZhangC.WangX.HongW.SunJ.et"/>
  <result pre="infectivity in vitro.Sci. China Life Sci.601396â€&quot;1398. 10.1007/s11427-017-9192-029134418 LiM.ZhaoL.ZhangC.WangX.HongW.SunJ.et al. (2018)." exact="Dengue" post="immune sera enhance Zika virus infection in human peripheral"/>
  <result pre="Life Sci.601396â€&quot;1398. 10.1007/s11427-017-9192-029134418 LiM.ZhaoL.ZhangC.WangX.HongW.SunJ.et al. (2018). Dengue immune sera enhance" exact="Zika" post="virus infection in human peripheral blood monocytes through Fc"/>
  <result pre="monocytes through Fc gamma receptors.PLoS One13:e0200478. 10.1371/journal.pone.020047830044839 LiangH.YangR.LiuZ.LiM.LiuH.JinX. (2018). Recombinant" exact="Zika" post="virus envelope protein elicited protective immunity against Zika virus"/>
  <result pre="(2018). Recombinant Zika virus envelope protein elicited protective immunity against" exact="Zika" post="virus in immunocompetent mice.PLoS One13:e0194860. 10.1371/journal.pone.019486029590178 LimM. Q.KumaranE. A."/>
  <result pre="function of dengue capsid and NS3-specific memory T Cells Toward" exact="Zika" post="Virus.Front. Immunol.9:2225. 10.3389/fimmu.2018.0222530327651 Limon-FloresA. Y.Perez-TapiaM.Estrada-GarciaI.VaughanG.Escobar-GutierrezA.Calderon-AmadorJ.et al. (2005). Dengue virus"/>
  <result pre="Cells Toward Zika Virus.Front. Immunol.9:2225. 10.3389/fimmu.2018.0222530327651 Limon-FloresA. Y.Perez-TapiaM.Estrada-GarciaI.VaughanG.Escobar-GutierrezA.Calderon-AmadorJ.et al. (2005)." exact="Dengue" post="virus inoculation to human skin explants: an effective approach"/>
  <result pre="transgenic mice.PLoS One12:e0184207. 10.1371/journal.pone.018420728863168 LiuY.LiuJ.DuS.ShanC.NieK.ZhangR.et al. (2017). Evolutionary enhancement of" exact="Zika" post="virus infectivity in Aedes aegypti mosquitoes.Nature545482â€&quot;486. 10.1038/nature2236528514450 LiuI. J.ChiuC."/>
  <result pre="T. (2016). AXL-Mediated Productive Infection of Human Endothelial Cells by" exact="Zika" post="Virus.Circ. Res.1191183â€&quot;1189. 10.1161/CIRCRESAHA.116.30986627650556 LokS. M.KostyuchenkoV.NybakkenG. E.HoldawayH. A.BattistiA. J.Sukupolvi-PettyS.et al."/>
  <result pre="of surface glycoproteins.Nat. Struct. Mol. Biol.15312â€&quot;317. 10.1038/nsmb.138218264114 MaW.LiS.MaS.JiaL.ZhangF.ZhangY.et al. (2016)." exact="Zika" post="virus causes testis damage and leads to male infertility"/>
  <result pre="(2004). Emerging flaviviruses: the spread and resurgence of Japanese encephalitis," exact="West Nile" post="and dengue viruses.Nat. Med.10(Suppl.), S98â€&quot;S109. 10.1038/nm114415577938 ManoffS. B.SausserM.Falk RussellA.MartinJ.RadleyD.HyattD.et"/>
  <result pre="in flavivirus-naive adults.Hum. Vaccin Immunother.152195â€&quot;2204. 10.1080/21645515.2018.154652330427741 MansuyJ. M.DutertreM.MengelleC.FourcadeC.MarchouB.DelobelP.et al. (2016)." exact="Zika" post="virus: high infectious viral load in semen, a new"/>
  <result pre="(1999). Infection of primary cultures of human Kupffer cells by" exact="Dengue" post="virus: no viral progeny synthesis, but cytokine production is"/>
  <result pre="RamosA. M.DaviH. P.IgleziasS. D.KanamuraC. T.et al. (2016). Pathology of congenital" exact="Zika" post="syndrome in Brazil: a case series.Lancet388898â€&quot;904. 10.1016/S0140-6736(16)30883-227372395 McCrackenM. K.GromowskiG."/>
  <result pre="La BarreraR.et al. (2017). Impact of prior flavivirus immunity on" exact="Zika" post="virus infection in rhesus macaques.PLoS Pathog.13:e1006487. 10.1371/journal.ppat.100648728771605 McGeeC. E.TsetsarkinK.VanlandinghamD."/>
  <result pre="MetzS. W.ThomasA.BrackbillA.ForsbergJ.MileyM. J.LopezC. A.et al. (2019). Oligomeric state of the" exact="ZIKV" post="E protein defines protective immune responses.Nat. Commun.10:4606. 10.1038/s41467-019-12677-631601808 MichlmayrD.AndradeP.GonzalezK.BalmasedaA.HarrisE."/>
  <result pre="10.1038/s41467-019-12677-631601808 MichlmayrD.AndradeP.GonzalezK.BalmasedaA.HarrisE. (2017). CD14(+)CD16(+) monocytes are the main target of" exact="Zika" post="virus infection in peripheral blood mononuclear cells in a"/>
  <result pre="paediatric study in Nicaragua.Nat. Microbiol.21462â€&quot;1470. 10.1038/s41564-017-0035-028970482 MinerJ. J.DiamondM. S. (2017)." exact="Zika" post="virus pathogenesis and tissue tropism.Cell Host Microbe21134â€&quot;142. 10.1016/j.chom.2017.01.00428182948 MitragotriS."/>
  <result pre="liquid jet injectors.Nat. Rev. Drug Discov.5543â€&quot;548. 10.1038/nrd207616816837 MlakarJ.KorvaM.TulN.PopovicM.Poljsak-PrijateljM.MrazJ.et al. (2016)." exact="Zika" post="virus associated with microcephaly.N. Engl. J. Med374951â€&quot;958. 10.1056/NEJMoa160065126862926 ModhiranN.WattersonD.MullerD."/>
  <result pre="Engl. J. Med374951â€&quot;958. 10.1056/NEJMoa160065126862926 ModhiranN.WattersonD.MullerD. A.PanettaA. K.SesterD. P.LiuL.et al. (2015)." exact="Dengue" post="virus NS1 protein activates cells via Toll-like receptor 4"/>
  <result pre="and immunogenicity results from three trials of a purified inactivated" exact="Zika" post="virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical"/>
  <result pre="randomised, double-blind, placebo-controlled clinical trials.Lancet391563â€&quot;571. 10.1016/S0140-6736(17)33106-929217375 MussoD.BossinH.MalletH. P.BesnardM.BroultJ.BaudouinL.et al. (2018)." exact="Zika" post="virus in French Polynesia 2013-14: anatomy of a completed"/>
  <result pre="the maternal-fetal interface.Science3361317â€&quot;1321. 10.1126/science.122003022679098 NettoE. M.Moreira-SotoA.PedrosoC.HoserC.FunkS.KucharskiA. J.et al. (2017). High" exact="Zika" post="virus seroprevalence in salvador, northeastern brazil limits the potential"/>
  <result pre="Disease.Bull. Hist Med.90193â€&quot;221. 10.1353/bhm.2016.004127374846 PantojaP.Perez-GuzmanE. X.RodriguezI. V.WhiteL. J.GonzalezO.SerranoC.et al. (2017)." exact="Zika" post="virus pathogenesis in rhesus macaques is unaffected by pre-existing"/>
  <result pre="P.MeurenL. M.CoelhoS. V. A.LucasC. G. O.MustafaY. M.Lemos MatassoliF.et al. (2017)." exact="Zika" post="Virus infects, activates, and crosses brain microvascular endothelial cells,"/>
  <result pre="al. (2007). The stoichiometry of antibody-mediated neutralization and enhancement of" exact="West Nile" post="virus infection.Cell Host Microbe1135â€&quot;145. 10.1016/j.chom.2007.03.00218005691 PorterK. R.EwingD.ChenL.WuS. J.HayesC. G.FerrariM.et"/>
  <result pre="10.1016/j.vaccine.2011.10.08522085548 PrasadV. M.MillerA. S.KloseT.SirohiD.BudaG.JiangW.et al. (2017). Structure of the immature" exact="Zika" post="virus at 9 A resolution.Nat. Struct. Mol. Biol.24184â€&quot;186. 10.1038/nsmb.335228067914"/>
  <result pre="A resolution.Nat. Struct. Mol. Biol.24184â€&quot;186. 10.1038/nsmb.335228067914 PrisantN.BujanL.BenichouH.HayotP. H.PaviliL.LurelS.et al. (2016)." exact="Zika" post="virus in the female genital tract.Lancet Infect Dis.161000â€&quot;1001. 10.1016/S1473-3099(16)30193-1"/>
  <result pre="10.1016/j.celrep.2019.01.03630726741 QianX.NguyenH. N.JacobF.SongH.MingG. L. (2017). Using brain organoids to understand" exact="Zika" post="virus-induced microcephaly.Development144952â€&quot;957. 10.1242/dev.14070728292840 QuickeK. M.BowenJ. R.JohnsonE. L.McDonaldC. E.MaH.Oâ€™NealJ. T.et"/>
  <result pre="microcephaly.Development144952â€&quot;957. 10.1242/dev.14070728292840 QuickeK. M.BowenJ. R.JohnsonE. L.McDonaldC. E.MaH.Oâ€™NealJ. T.et al. (2016)." exact="Zika" post="Virus Infects Human Placental Macrophages.Cell Host Microbe2083â€&quot;90. 10.1016/j.chom.2016.05.01527247001 Regla-NavaJ."/>
  <result pre="Regla-NavaJ. A.Elong NgonoA.ViramontesK. M.HuynhA. T.WangY. T.NguyenA. T.et al. (2018). Cross-reactive" exact="Dengue" post="virus-specific CD8(+) T cells protect against Zika virus during"/>
  <result pre="al. (2018). Cross-reactive Dengue virus-specific CD8(+) T cells protect against" exact="Zika" post="virus during pregnancy.Nat. Commun.9:3042. 10.1038/s41467-018-05458-030072692 RichnerJ. M.HimansuS.DowdK. A.ButlerS. L.SalazarV.FoxJ."/>
  <result pre="A.ButlerS. L.SalazarV.FoxJ. M.et al. (2017a). Modified mRNA vaccines protect against" exact="Zika" post="Virus Infection.Cell169:176. 10.1016/j.cell.2017.03.01628340344 RichnerJ. M.JaggerB. W.ShanC.FontesC. R.DowdK. A.CaoB.et al."/>
  <result pre="M.JaggerB. W.ShanC.FontesC. R.DowdK. A.CaoB.et al. (2017b). Vaccine mediated protection against" exact="Zika" post="virus-induced congenital disease.Cell170273.e12â€&quot;283.e12. 10.1016/j.cell.2017.06.04028708997 RivinoL.TanA. T.ChiaA.KumaranE. A.GrotenbregG. M.MacAryP. A.et"/>
  <result pre="S.SacramentoG. A.et al. (2019). Impact of preexisting dengue immunity on" exact="Zika" post="virus emergence in a dengue endemic region.Science363607â€&quot;610. 10.1126/science.aav661830733412 RothmanA."/>
  <result pre="is hierarchical.Mol. Immunol.113115â€&quot;119. 10.1016/j.molimm.2018.08.01130146122 Sanchez-San MartinC.LiT.BouquetJ.StreithorstJ.YuG.ParanjpeA.et al. (2018). Differentiation enhances" exact="Zika" post="virus infection of neuronal brain cells.Sci. Rep.8:14543. 10.1038/s41598-018-32400-730266962 SangkawibhaN.RojanasuphotS.AhandrikS.ViriyapongseS.JatanasenS.SalitulV.et"/>
  <result pre="10.1093/oxfordjournals.aje.a1139326496446 SapparapuG.FernandezE.KoseN.BinC.FoxJ. M.BombardiR. G.et al. (2016). Neutralizing human antibodies prevent" exact="Zika" post="virus replication and fetal disease in mice.Nature540443â€&quot;447. 10.1038/nature2056427819683 ShanC.MuruatoA."/>
  <result pre="D.MedeirosD. B. A.et al. (2017). A single-dose live-attenuated vaccine prevents" exact="Zika" post="virus pregnancy transmission and testis damage.Nat. Commun.8:676. 10.1038/s41467-017-00737-828939807 ShanC.XieX.LuoH.MuruatoA."/>
  <result pre="ShanC.XieX.LuoH.MuruatoA. E.LiuY.WakamiyaM.et al. (2019). Maternal vaccination and protective immunity against" exact="Zika" post="virus vertical transmission.Nat. Commun.10:5677. 10.1038/s41467-019-13589-131831806 SharmaM.GlasnerD. R.WatkinsH.Puerta-GuardoH.KassaY.EganM. A.et al."/>
  <result pre="G.et al. (2016). The 3.8 A resolution cryo-EM structure of" exact="Zika" post="virus.Science352467â€&quot;470. 10.1126/science.aaf531627033547 Slon-CamposJ. L.DejnirattisaiW.JaggerB. W.Lopez-CamachoC.WongwiwatW.DurnellL. A.et al. (2019). A"/>
  <result pre="virus.Science352467â€&quot;470. 10.1126/science.aaf531627033547 Slon-CamposJ. L.DejnirattisaiW.JaggerB. W.Lopez-CamachoC.WongwiwatW.DurnellL. A.et al. (2019). A protective" exact="Zika" post="virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement"/>
  <result pre="antibody-dependent enhancement of dengue infection.Nat. Immunol.201291â€&quot;1298. 10.1038/s41590-019-0477-z31477918 SpiteriG.SudreB.SeptfonsA.BeauteJ.collab: The European," exact="Zika" post="Surveillanceet al. (2017). Surveillance of Zika virus infection in"/>
  <result pre="10.1038/s41590-019-0477-z31477918 SpiteriG.SudreB.SeptfonsA.BeauteJ.collab: The European, Zika Surveillanceet al. (2017). Surveillance of" exact="Zika" post="virus infection in the EU/EEA, June 2015 to January"/>
  <result pre="al. (2016). Specificity, cross-reactivity, and function of antibodies elicited by" exact="Zika" post="virus infection.Science353823â€&quot;826. 10.1126/science.aaf850527417494 SunJ.LiM.WangY.HaoP.JinX. (2017). Elaboration of tetravalent antibody"/>
  <result pre="envelope sequence.Vaccine356308â€&quot;6320. 10.1016/j.vaccine.2017.09.06328987441 SzabaF. M.TigheM.KummerL. W.LanzerK. G.WardJ. M.LanthierP.et al. (2018)." exact="Zika" post="virus infection in immunocompetent pregnant mice causes fetal damage"/>
  <result pre="Pathog.14:e1006994. 10.1371/journal.ppat.100699429634758 TamhankarM.PattersonJ. L. (2019). Directional entry and release of" exact="Zika" post="virus from polarized epithelial cells.Virol. J.16:99. 10.1186/s12985-019-1200-231395061 TebasP.RobertsC. C.MuthumaniK.ReuschelE."/>
  <result pre="dengue vaccines.Vaccine363411â€&quot;3417. 10.1016/j.vaccine.2018.02.06229525283 VermillionM. S.LeiJ.ShabiY.BaxterV. K.CrillyN. P.McLaneM.et al. (2017). Intrauterine" exact="Zika" post="virus infection of pregnant immunocompetent mice models transplacental transmission"/>
  <result pre="mice.Front. Microbiol.10:1113. 10.3389/fmicb.2019.0111331134046 WeaverS. C.CostaF.Garcia-BlancoM. A.KoA. I.RibeiroG. S.SaadeG.et al. (2016)." exact="Zika" post="virus: History, emergence, biology, and prospects for control.Antiviral. Res.13069â€&quot;80."/>
  <result pre="infection.J. Virol.8811383â€&quot;11394. 10.1128/JVI.01108-1425056881 WenJ.Elong NgonoA.Regla-NavaJ. A.KimK.GormanM. J.DiamondM. S.et al. (2017a)." exact="Dengue" post="virus-reactive CD8(+) T cells mediate cross-protection against subsequent Zika"/>
  <result pre="(2017a). Dengue virus-reactive CD8(+) T cells mediate cross-protection against subsequent" exact="Zika" post="virus challenge.Nat. Commun.8:1459. 10.1038/s41467-017-01669-z29129917 WenJ.TangW. W.SheetsN.EllisonJ.SetteA.KimK.et al. (2017b). Identification"/>
  <result pre="virus challenge.Nat. Commun.8:1459. 10.1038/s41467-017-01669-z29129917 WenJ.TangW. W.SheetsN.EllisonJ.SetteA.KimK.et al. (2017b). Identification of" exact="Zika" post="virus epitopes reveals immunodominant and protective roles for dengue"/>
  <result pre="mosquitoes, mice, and rhesus monkeys.Vaccine214307â€&quot;4316. 10.1016/s0264-410x(03)00488-214505913 Wilder-SmithA.VanniceK.DurbinA.HombachJ.ThomasS. J.ThevarjanI.et al. (2018)." exact="Zika" post="vaccines and therapeutics: landscape analysis and challenges ahead.BMC Med.16:84."/>
  <result pre="Control: New Edition.Geneva: WHO. collab: World Health Organization [WHO] (2017)." exact="Dengue" post="vaccine: WHO position paper, July 2016 - recommendations.Vaccine351200â€&quot;1201. 10.1016/j.vaccine.2016.10.07028185744"/>
  <result pre="10.1073/pnas.130633311023686453 ZouJ.XieX.LuoH.ShanC.MuruatoA. E.WeaverS. C.et al. (2018). A single-dose plasmid-launched live-attenuated" exact="Zika" post="vaccine induces protective immunity.EBioMedicine3692â€&quot;102. 10.1016/j.ebiom.2018.08.05630201444"/>
 </snippets>
</snippetsTree>
